Sitemap

Pages

• 2021 Dr. David Green Recognition Program
• About Neuromuscular Disorders
  • What are NMDs?
  • Signs and Symptoms
  • Types of Neuromuscular Disorders
  • Frequently Asked Questions
  • We call it a Neuromuscular Disorder
  • Webinars
    • Coping with Stress & Anxiety During COVID-19
    • COVID-19: Nutrition, Supplements & Healthy Eating
    • MDC Neuromuscular Conference
    • Virtual/Tele-Physiotherapy During COVID-19
    • COVID-19, NMDS & Respiratory Health
    • Caregiving In The Time of COVID-19
    • Patient/Client & Family-Centred Engagement
    • Speech, Swallowing & Communication
• calendars
• Caregiver Retreat – Saskatchewan, Registration Form
• Complaint Process
• Contact Us
• COVID-19 Vaccines and NMDs
• Défi Gratte Ciel
• Delegate Resources
• Donate
• Family Member Registration Form
• Friend & Acquaintance Registration Form
• Healthcare Professionals
• Home
• Home – Beta
• Join the Community
• Legacy and Estate Giving — copy
• Managing Communication Preferences
• NMDs and COVID-19
  • What you need to know about COVID-19
  • Helpful Links to Stay up to Date
  • General FAQs
  • Activities
  • Ask the experts
  • Urgent Appeal
• Planned Giving
• Register
• Subscribe
• testdonation
• Thank You Family Member!
• Thank You for Choosing Your Contact Preferences!
• Thank You for Submitting our Healthcare Professional and Scientist Registration Questionnaire
• Thank You for Your Interest in Volunteering at MDC
• Thank You for Your Participation in the 2021 Dr. David Green Recognition Program
• Thank You, Friend or Acquaintance!
• About MDC
  • Mission, Vision and Values
  • History
  • Our Team
  • Financial Statements
  • Frequently Asked Questions
• Get Involved
  • Fire Fighters
    • National Fire Fighter Relations Committee
    • Fire Fighter Team
  • Join our Community
  • Participate in an Event
  • Organize an Event
  • Volunteer
    • Volunteer Testimonials
    • Recognizing Our Volunteers
      • Artist Profiles
      • Recipent profiles
    • Volunteer Spotlight
  • Community Champions
  • Career Opportunities
• Services and Support
  • Systems Navigation
    • Register as a Client
    • Equipment Program
    • Community Services Fund
    • Educational Resources
    • Family and Caregiver Retreats
  • Research
    • Clinical Trials
      • About Clinical Trials
      • Before Enrolling
      • Frequently Asked Questions
    • Research News
    • Research Grants
      • Funding Partners
    • Research Outcomes
    • Research Hotline
    • Driving Research Forward
  • Advocacy
    • Access to Treatments
    • Accessible Canada Act
    • Self Advocacy
    • Transition to Adulthood
    • Accessible Travel
    • Journey Mapping
    • imPORTND Patient-Oriented Research Training
    • BIND Study
    • DIAP
    • Advocacy News
  • Newborn Screening
  • Need Help?
• Volunteer Application
• Gifts and Giving
  • Monthly Donations
  • Legacy and Estate Giving
    • Gift of Securities
    • Gifts in Your Will
    • MDC’s Contact and Legal information
    • Other Ways to Give
  • Leadership Gifts
  • Workplace Giving
  • Corporate Sponsorship
  • Donor Bill of Rights
• We call it a Neuromuscular Disorder
  • Duchenne
  • Facioscapulohumeral muscular dystrophy
  • Myotonic Dystrophy
  • Spinal Muscular Atrophy
  • Limb-Girdle Muscular Dystrophy
  • Pompe
• Newsroom
  • Reports
  • Press Releases
  • Newsletters
    • Archive
  • Testimonials and Stories
• Researchers
  • Research Funding Strategy
  • Translational Science and Clinical Research Grants
  • Medical and Scientific Advisory Committee
  • Funded Grants and Awards
    • Grant Descriptions
  • Fellowship Awards
• Events
  • Walk and Roll for MDC
  • High Rise Challenge
  • Galas & Cabarets
  • Fill the Boot
  • Mobilize Change: How to advocate
  • 2024 Atlantic Spring Raffle
  • Family and Caregiver Retreats
  • Holiday Ornament Campaign
• News
• Privacy Policy
• Site Credits
• Shared Decision Making Support

Posts by category

• Category: Advocacy
  • 100% of Canada is now screening infants for spinal muscular atrophy (SMA)
  • Help families, like Danielle’s, get the answers and support they so desperately need.
  • UNWAVERING COMMITMENT: FIRE FIGHTERS AND MUSCULAR DYSTROPHY CANADA CELEBRATE 70TH ANNIVERSARY
  • LET’S PARTNER TO ACHIEVE EVEN MORE! TOGETHER, WE HAVE ACCOMPLISHED SO MUCH AND WE KNOW THERE IS MORE TO DO
  • BRINGING THE NEUROMUSCULAR COMMUNITY TOGETHER TO CONNECT, REST AND SHARE EXPERIENCES
  • WALK & ROLL SEASON HAS OFFICIALLY STARTED
  • New locations added to 2024 Walk and Roll for Muscular Dystrophy Canada
  • MDC AND PARTNERS LAUNCH CENTRAL HUB FOR NMD SPECIALISTS – A CANADIAN FIRST!
  • TOGETHER, WE’RE HELPING BREAK DOWN BARRIERS FOR CHILDREN WITH NMDS
  • WE HEARD YOU: BREAKING DOWN THE BARRIERS OUR COMMUNITY EXPERIENCE MOST
  • YOU ARE BUILDING THE FUTURE OF RESEARCH AND CARE
  • FIRE FIGHTERS IGNITE JOY AND MAKE LASTING CONNECTIONS
  • CELEBRATING VOLUNTEERS AS THEY CHAMPION CHANGE ACROSS CANADA
  • MYASTHENIA GRAVIS JOURNEY MAPPING: AN INSIDE LOOK
  • LET’S FIND YOUR PATHWAY OF POSSIBILITIES
  • Mark got what he needed to get back outside and explore nature!
  • Community Statement: Update on Deflazacort®/Calcort® Availability
  • Your support has improved outcomes for thousands of Canadians, like Ben
  • Quebec joins the ranks of provinces screening newborns for life-threatening disorder
  • Freya’s life has been changed, thanks to your amazing support
  • Abilities (at the) Centre of new location for Walk and Roll for Muscular Dystrophy Canada
  • BREAKING DOWN BARRIERS FOR THE NEUROMUSCULAR COMMUNITY
  • VALUE OF A MONTHLY GIFT
  • GETTING A CLOSER LOOK AT THE SOCIAL AND ECONOMIC COSTS OF NEUROMUSCULAR DISORDERS
  • TOGETHER WE ARE BREAKING DOWN BARRIERS TO IMPROVE ACCESS TO THERAPIES FOR CANADIANS AFFECTED BY FSHD
  • RAISING THE BAR FOR NEUROMUSCULAR DISORDER RESEARCH AND CLINICAL CARE IN CANADA
  • MDC IS HERE FOR YOU!
  • Muscular Dystrophy Canada, AccessNow teaming up to make travel more accessible for people with disabilities
  • Break down barriers for people like Christina today!
  • FUNDING FOR INNOVATIVE THERAPIES FOR HEREDITARY ATAXIAS
  • Celebrating outstanding commitment through the Dr David Green Awards
  • Funding for first-ever National Strategy for Drugs for Rare Diseases announced
  • A Partnership to Fund Research for Hereditary Ataxias
  • MDC, CNDR, NMD4C partner to ensure Canadians can access FSHD cure(s)
  • Community Statement: Update on Deflazacort®/Calcort® Availability
  • Neuromuscular disorders do not discriminate. Nor do they take a break over the holiday season.
  • Make an impact for someone like Brody today
  • Give someone like Elvin the gift of independence
  • Support someone like Elude today
  • Make a life-changing difference for someone like Lucas
  • Canadians like Johnny need your support now
  • B.C. newborn screening expands; early detection improves quality of life
  • Celebrating the heart and soul of the Canadian neuromuscular disorder community
  • CADTH makes final recommendation on adult access to treatment
  • Global Alliance for Myotonic Dystrophy
  • Quebec announces policy on rare diseases
  • All Canadians deserve access to life-changing treatments
  • Disability Inclusion Action Plan consultations set to begin in May
  • Newborns in Alberta can get screened for spinal muscular atrophy as part of pilot project with MDC
  • Saskatchewan expanding newborn screening for Spinal Muscular Atrophy (SMA)
  • Muscular Dystrophy Canada and Independent Living Canada partner to help lead the development of Canada’s first ever Disability Inclusion Action Plan
  • AccessAbility Program to increase disability and inclusion education in classrooms
  • Muscular Dystrophy Canada joins forces internationally to impact greater change at home
  • Recognizing dedication and passion beyond measure
  • National collaboration awards funding for newborn screening in spinal muscular atrophy (SMA)
  • Call for Project Proposals: Newborn Screening for Spinal Muscular Atrophy in Canada
  • Reduce the timing between doses for patients with neuromuscular diseases
  • MDC Change Agents 
  • Researchers from across Canada join The Tenaquip Foundation’s Walk4MD to raise awareness and funding for neuromuscular disorder community
  • MDC’s Response to the CADTH and INESSS Recommendations for Onasemnogene abeparvovec: A Call for Newborn Screening
  • Response to the Federal Government on Building a National Strategy for High-Cost Drugs for Rare Diseases
  • Muscular Dystrophy Canada Receives National Accreditation
  • Muscular Dystrophy Canada calls on provincial governments to prioritize persons affected by neuromuscular disorders for COVID-19 vaccine
  • Rare Disease Day
  • Your Impact on the Neuromuscular Community in 2020 was Profound
  • MDC Statement
  • Don’t Forget Me This Holiday Season
  • WMS Challenge
  • Double Your Impact Today
  • The Tenaquip Foundation Walk for Muscular Dystrophy raising funds, hope and unity in new ways
  • Feel Good Friday Client Spotlight: Willms Family
  • Feel Good Friday Client Spotlight: Ken M. Kramer
  • National Volunteer Week 2020
  • COVID – 19: What you should know about this novel coronavirus
  • Response to PMPRB Draft Guidelines Consultation
  • Key topics in Spinal Muscular Atrophy research discussed at first ever Muscular Dystrophy Canada SMA Research Summit
  • Major Improvement in CRISPR Technology Could Fix Genetic Spelling Mistakes: Implications for Neuromuscular Disorders?
  • Celebrate Muscular Dystrophy Month With Us
  • Alberta Fourth Province to Expand Access to Spinraza™ for Patients Impacted with Spinal Muscular Atrophy
  • More Patients Impacted with Spinal Muscular Atrophy in Ontario to Gain Access to Spinraza™
  • Patients Living with Spinal Muscular Atrophy (SMA) in the Province of Saskatchewan Gain Access to Spinraza™
  • Federal Government Commits to National Strategy to Improve Access to Rare Disease Drugs
• Category: Chapter
• Category: Education
  • RESEARCH TRAINING IS AVAILABLE FOR YOU!
  • Post-doctoral Fellowships to advance neuromuscular research
• Category: Fire Fighters
  • Fire Fighters Fill the Boot Campaign Goes Virtual
  • Important Update on Phone Solicitations
  • Brayden’s Journey
• Category: Fundraising
  • The 2024 Walk & Roll for Muscular Dystrophy Canada was a huge success thanks to you!
  • Donor support makes a difference
  • Important Update on Phone Solicitations
  • Important Update on Phone Solicitations
  • Give the gift of a new beginning
  • Change someone’s tomorrow – today!
  • You can bring people together, even when we have to stay apart
  • Important Update on Phone Solicitations
  • MDC Urgently Needs Your Help
• Category: Healthcare
  • 100 percent of Canada is now screening infants for spinal muscular atrophy, a potentially fatal disorder
  • QUEBEC JOINS THE RANKS OF PROVINCES SCREENING NEWBORNS FOR SMA
  • Governments across Canada urged to close current gap in care for debilitating neuromuscular disease by funding treatment advancements
  • Neuromuscular Disease Network for Canada Awarded 5-Year Grant from CIHR-IMHA and Funding from MDC to Strengthen Canadian Neuromuscular Research and Care
  • First of its kind: New program will increase patient engagement in neuromuscular disorder research
  • Muscular Dystrophy Canada Is Participating in Clinical Trials Quebec’s Pilot Project
  • New Ontario-led project to have national impact on newborn screening
  • Clinical Fellowships support future Canadian leaders in neuromuscular care
  • Screening newborns for spinal muscular atrophy closer to reality in the Maritimes
• Category: MDC
  • Muscular Dystrophy Canada’s Annual Report is now available
  • 2022-2023 YEAR IN REVIEW: ANNUAL REPORT HIGHLIGHTS
  • Important Update on Phone Solicitations
  • Join our Board of Directors
  • Notice of 2021 Annual General Meeting of Members
  • Progress on national newborn screening for SMA
  • MDC funds seven new projects to propel research forward during challenging times
  • Muscular Dystrophy Canada appoints new CEO
  • New partnership will provide cough assists for adults in British Columbia
  • Stacey Lintern appointed Interim CEO at Muscular Dystrophy Canada
  • Muscular Dystrophy Canada makes the difficult decision to reduce staff
  • Notice of Annual General Meeting
  • MDC Welcomes Daria Wojtal as Director of Research
• Category: Newsletters
  • Clinical Trials in Canada for Neuromuscular Disorders Are on the Rise
  • Opening Doors: Navigating University with Neuromuscular Conditions
  • YOU’RE MOVING RESEARCH FORWARD
  • Category: 2022 Summer
    • TEN DOWN, THREE TO GO
    • RESEARCH FUNDING IS CHANGING NEUROMUSCULAR LANDSCAPE IN CANADA
    • Meet the Fellows
    • YOU’RE HELPING MAKE CLASSROOMS A SAFE AND ACCEPTING PLACE FOR ALL
    • Additions to the Equipment Program Funding!
    • STEP UP FOR THE NEUROMUSCULAR COMMUNITY
    • THE BOOTS ARE BACK AND WE NEED YOUR HELP!
    • Shad’s R&R annual golf tournament
  • Category: Spring 2023
  • Category: Spring 2024
  • Category: Summer 2024
  • Category: Winter 2023
  • Category: Winter 2024
• Category: Press Releases
  • Moving Research & Discovery Forward – The 2024 Neuromuscular Clinical and Translational Research Grant Recipients
  • Donors make it possible to invest in both neuromuscular disorder research and care, now and for the future
  • MDC funds nine new projects to propel research forward and break down barriers
  • $360,000 in fellowships awarded to advance neuromuscular research and healthcare
  • International research competition results in funding for innovative Collagen 6- related dystrophy research projects
  • Announcing Muscular Dystrophy Canada’s 2022 Research Grant Competition winners!
  • Providing a path to practice: fellowship funding to support top-ranked Canadian clinicians
  • New Partnership Offers Access to Shared Decision Making Support in Ontario
  • NMD4C propelling research forward for patients, scientists and clinicians
  • MDC presents CADTH With GMG Patient Submission
  • Treating Duchenne Muscular Dystrophy Focus of New Research Partnership
• Category: Research
  • NMD4C and MDC Launch Postdoctoral Fellowship Funding Competition
  • How new medicines are reviewed, approved and funded in Canada
  • CADTH REVIEW AND SPINRAZA
• Category: Services
• Category: Testimonials
  • THANKS TO YOU, ALEX HAS GAINED GREATER MOBILITY!
  • Finding cures for neuromuscular disorders in our lifetime
  • Rare Disease Day 2022
  • You can break down barriers for Canadians living with a neuromuscular disorder
  • The DeVries Family
  • Rachel Andrews Story
• Category: Uncategorized
  • Dr David Green Awards shines the spotlight on outstanding volunteers
• Category: Volunteer Testimonials

projects

• Maternal and Neonatal Outcomes of Cesarean Deliveries in Women with Muscular Dystrophy
• A New in vitro Eccentric Muscle Contraction Assay For Drug Repurposing for Muscular Dystrophy
• Angiopoietin-1 enhances microdystrophin replacement therapy for Duchenne muscular dystrophy
• Efficacy of wheelchair skills training to improve mobility for people with ARSACS and DM1
• Single nucleus RNAseq biomarkers in adult-onset muscle diseases
• Maternal transfer of AAV vectors: a minimally invasive approach to deliver SMN-gene therapy for SMA
• Elucidating DYSF pre-mRNA splicing to inform therapeutic avenues for dysferlinopathies
• Utilizing AI to Predict Non-Invasive Ventilation Need in Neuromuscular Disorders: A Proof of Concept
• Understanding the impact of central nervous system impairments on daily life in myotonic dystrophy
• Correction of intra-exonic insertions and deletions in DMD gene using CRISPR-Cas9 technologies
• Using 3D human iPSC-derived skeletal muscle modelling to elucidate the molecular mechanisms and develop new therapies for satellite cell-opathies
• Clinical Fellowship Recipient
• Clinical Fellowship Recipient
• Clinical Fellowship Recipient
• Advanced human myo-fibrogenic 3D models for COL6 disease modeling and therapy development
• Further steps toward an RNA-based therapy for COL6-RD
• Evaluating the impact of stop variants on MLIP’s (Muscular LMNA-Interacting Protein) function in muscle
• How genealogies (family histories) can help us understand myotonic dystrophy type 1
• Therapy development for centronuclear myopathy caused by DNM2 gene changes
• Pre-clinical testing of novel pharmacological inhibitors of toxic DMPK mRNA in models of myotonic dystrophy type 1
• Reimagining rehabilitation for SMA: Patient and family perspectives
• B-FIT! Taking exercise away from the hospital into the home environment in people with oculopharyngeal muscular dystrophy
• Muscle MRI in neuromuscular disorders: The era of artificial intelligence
• Dietary protein requirements in adults with muscular dystrophy
• Establishing the top ten research priorities for respiratory care of childhood neuromuscular disorders
• Targeting mitochondrial dynamics and metabolites to restore muscle stem cell function in Duchenne Muscular Dystrophy
• Determining the Therapeutic Potential of AMP-activated Protein Kinase in Myotonic Dystrophy Type 2
• Targeting the Perivascular MuSC Niche for the Treatment of Muscular Dystrophy
• Clinical fellowship recipient
• Clinical fellowship recipient
• Clinical fellowship recipient
• Role of CARM1 in satellite cell dysfunction in Duchenne muscular dystrophy (DMD)
• Determining the molecular mechanisms and environmental modifiers of progressive liver disease in X-linked myotubular myopathy
• Clinical Fellowship – EMG and Neuromuscular Medicine
• Clinical Fellowship – EMG and Neuromuscular Medicine
• Clinical Fellowship - EMG and Neuromuscular Medicine
• QP-OPMD: Quantitative MRI Imaging to Assess Progression in Oculopharyngeal Muscular Dystrophy
• The Transition of Teenagers with Spinal Muscular Atrophy to a Multi-Disciplinary Adult Program
• Exploring the impact of Spinal Bulbar Muscular Atrophy on persons self-identifying as Indigenous
• Building a screenable human 3D neuromuscular junction model for neuromuscular disorders
• Genome-wide DNA methylation profile in Duchenne Muscular Dystrophy
• Measuring balance in chronic inflammatory demyelinating polyneuropathy
• Endurance training as a novel therapeutic strategy for Myotonic Dystrophy type 1
• Mitochondrial-targeted therapies to improve Duchenne muscular dystrophy outcomes
• Motor network connectivity in spinal muscular atrophy: new pathways for intervention
• When wait time means better services: Creating an interactive waiting room to inform MD patients on various topics in research
• Safety and efficacy of a possible epigenetic therapy for FSHD muscular dystrophy
• Enhancing the efficacy of antisense oligonucleotide therapy for FSHD
• Improving myoblast transplantation outcomes via pharmacological reprogramming
• Targeting defective stem cells in a preclinical model of DM1
• Promoting Muscle Repair by Pharmacological Inhibition of eIF2a Dephosphorylation
• A pharmacogenetic pipeline for Charcot-Marie-Tooth Disease
• Human iPSC-derived neurons as a model of congenital myotonic dystrophy type 1
• Non-viral, immune-modulatory nanoparticles for delivery of CRISPR/Cas9 as a treatment intervention for Duchenne Muscular Dystrophy
• A better trunk and lower limb control for a better mobility: Assessment of a re-entrainment program in Autosomal recessive spastic ataxia of Charlevoix-Saguenay
• A Population-based Cohort Study of Pregnancy Outcomes in Women with Myasthenia Gravis
• Denosumab for the Treatment of Osteoporosis in Boys with Duchenne Muscular Dystrophy: A Pilot Study
• Identification of modifiers underlying the variable phenotypes of RYR1 myopathy
• Reverse translation from the diabetes clinic to pre-clinical muscular dystrophy
• Canonical disease features in a novel mouse model of SMA type III and IV
• Muscle strength reference values for adults: a critical need in NMD
• Therapeutic potential of CK1 agonists in inherited peripheral neuropathies
• Profiling granzymes in inflammatory neuromuscular diseases
• CRISPR mediated gene editing: a novel therapeutic strategy for nemaline myopathy
• Empowering caregivers to better manage DM patients’ neurobehavioral symptoms
• Patient preferences in treatments for myasthenia gravis: a DCE experiment
• A multidimensional single-cell approach to understand muscle dystrophy
• A Virtual Transition Intervention for Children and Adults Transitioning To Home Ventilation in Ontario: A Pragmatic Randomized Controlled Trial
• Exosomal Delivery of Wnt7a for treating Duchenne Muscular Dystrophy
• Interventional Study of Expiratory Muscle Strength Training as a Treatment for Muscle Disease
• NMD4C: An integrated research network for patients, scientists, and clinicians to improve outcomes and access to therapies for patients with neuromuscular disorders in Canada